Compare EVEX & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVEX | SDGR |
|---|---|---|
| Founded | 2020 | 1990 |
| Country | United States | United States |
| Employees | 198 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 835.9M | 925.8M |
| IPO Year | N/A | 2020 |
| Metric | EVEX | SDGR |
|---|---|---|
| Price | $2.86 | $12.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $6.88 | ★ $21.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | N/A | $0.76 |
| Revenue Next Year | $11,676.47 | $4.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $2.34 | $10.95 |
| 52 Week High | $7.70 | $27.63 |
| Indicator | EVEX | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 53.47 | 59.52 |
| Support Level | $2.34 | $11.08 |
| Resistance Level | $3.18 | $13.33 |
| Average True Range (ATR) | 0.14 | 0.74 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 41.76 | 81.89 |
Eve Holding Inc is a provider of Urban Air Mobility solutions. The company's operating segments are; eVTOL that includes; the design and production of electric vertical take-off and landing vehicles (eVTOLs) including fixed wing and helicopter operators, as well as lessors that purchase and manage aircraft on behalf of operators; Service and Operations Solutions segment which includes a portfolio of maintenance and support services focused on its and third-party eVTOLs; and the UATM segment, a new Urban Air Traffic Management system designed to allow eVTOLs to operate safely and efficiently in dense urban airspace alongside conventional aircraft and drones.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.